The company has demonstrably advanced the development of a new treatment for amyloid heart disease, employing the investigational drug. Early trial data reveals potential benefits for those diagnosed with the https://attr-cm820715.theblogfairy.com/40880270/bridgebio-advances-amyloidosis-treatment-through-attruby